Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
In a post-earnings update, Eli Lilly reported 48% revenue growth in the second quarter of 2026, attributing the performance largely to ongoing cardiometabolic medicine demand and indicating it has moved its full-year outlook higher.
THE APEX TIMES
THE APEX TIMES
A new Trefis note highlights how derivatives trading can embed competing scenarios for Eli Lilly stock, leaving investors exposed to outcomes that could play out very differently.
THE APEX TIMES
The company says it expects to have its mFlusiva program ready for the 2026-2027 flu season, placing near-term payoff further out than investors typically want.
THE APEX TIMES
A new market commentary argues Johnson & Johnson’s shareholder return profile may fit investors looking for dividends, while offering limited specifics in the published excerpt.
THE APEX TIMES
The ruling deals a setback to plaintiffs alleging the companies used legal pressure to block access to compounded versions of GLP-1 therapies.
THE APEX TIMES
In remarks tied to its latest earnings discussion, Moderna indicated it will hold to its 2026 growth target as it adjusts spending plans, while pushing forward programs across flu, oncology, and rare diseases toward upcoming milestone events.
THE APEX TIMES
The biotech said it has launched a first-in-human study in Canada for an investigational mRNA vaccine targeting Bundibugyo ebolavirus, a strain of Ebola that has no approved vaccine in the segment the company is pursuing.
THE APEX TIMES
The new report, distributed via a GlobeNewswire announcement syndicated on Yahoo Finance, examines the global influenza vaccine market and includes company profiles of Pfizer, GSK, Sanofi and Moderna.
THE APEX TIMES
Despite reporting higher second-quarter sales and profit, CVS Health drew a sharp selloff in early August after lifting its 2026 outlook and expanding its relationship with Eli Lilly around GLP-1 medicines.
